Carlos Encinas, Ph.D., M.B.A.

Carlos joined Skysong Innovations in August of 2018 and was responsible for establishing international tech transfer collaborations between Skysong Innovations and other universities.

Prior to joining the Skysong Innovations team, Encinas served as the Assistant Director of the Office of Industry and Research Collaboration at Arizona State University, negotiating and administering industry-related agreements for the university, including MTAs, CDAs, and sponsored research agreements.

Previously, Encinas held the position of Director of the Cedars-Sinai Medical Center (CSMC) Technology Transfer Office in Los Angeles, where he was directly responsible for the licensing of Rifaximin for the treatment of SIBO to Salix Pharmaceutical, later acquired by Valeant. During his time at CSMC, and as an independent professional, he participated and was actively involved in the creation and development of research and technology transfer centers in Central and Eastern Europe, Western Europe and Latin America.

Encinas has served in different leadership positions in a variety of technology-based companies. His experience includes CFO, COO, CSO, senior management and advisory role for start-ups in the US, Europe and South America. He has helped found several companies (BioLabs Sciences, AmerStem, PigMass, ArXTech), focusing mainly on early stage development of life sciences and green technologies.

Encinas holds a Ph.D. in Molecular and Cellular Biology and an MBA with an emphasis in Finance and Entrepreneurship from the University of Arizona.